MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
LeMaitre Vascular Income Statement 2011-2026 | LMAT
Annual Income Statement LeMaitre Vascular
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.07 B | 1.55 B | 1.11 B | 1.06 B | 811 M | 707 M | 462 M | 671 M | 419 M | 259 M | 132 M | 122 M | 92.4 M | 89.8 M |
Shares |
22.5 M | 22.2 M | 22 M | 21.2 M | 20.2 M | 19.8 M | 19.4 M | 19 M | 18.5 M | 17.8 M | 16.6 M | 15.3 M | 15.2 M | 15.5 M |
Historical Prices |
92.2 | 69.8 | 50.3 | 50.1 | 40.1 | 35.1 | 22.8 | 30.5 | 24.1 | 16.2 | 7.07 | 7.28 | 5.13 | 5.2 |
Net Income |
44 M | 30.1 M | 20.6 M | 26.9 M | 21.2 M | 17.9 M | 22.9 M | 17.2 M | 10.6 M | 7.76 M | 3.92 M | 3.2 M | 2.57 M | 2.14 M |
Revenue |
220 M | 193 M | 162 M | 154 M | 129 M | 117 M | 106 M | 101 M | 89.2 M | 78.4 M | 71.1 M | 64.5 M | 56.7 M | 57.7 M |
Cost of Revenue |
69 M | 66.4 M | 56.8 M | 53 M | 44.7 M | 37.4 M | 31.6 M | 30.2 M | 26.2 M | - | - | - | - | - |
Gross Profit |
151 M | 127 M | 105 M | 101 M | 84.6 M | 79.9 M | 73.9 M | 70.7 M | 62.9 M | 54.2 M | 48.4 M | 45.1 M | 40.9 M | 40.2 M |
Operating Income |
52.3 M | 36.7 M | 26.8 M | 36.4 M | 28.8 M | 21.2 M | 28.2 M | 21.1 M | 16.3 M | 11.5 M | 6.34 M | 4.52 M | 4.24 M | 3.69 M |
Interest Expense |
205 K | - | - | 2.22 M | 1.31 M | - | 2 K | 21 K | 14 K | - | 5 K | 12 K | 1 K | - |
EBITDA |
61.9 M | 46.2 M | 36.3 M | 47.5 M | 37.2 M | 26.6 M | 25.1 M | 25.2 M | 19.9 M | 14.5 M | 10.4 M | 7.31 M | 6.23 M | 7.24 M |
Operating Expenses |
98.6 M | 90.3 M | 78.1 M | 65 M | 55.8 M | 58.7 M | 53.2 M | 49.6 M | 46.6 M | 43 M | 41.3 M | 40.6 M | 36.9 M | 35 M |
General and Administrative Expenses |
36.3 M | 31.8 M | 28.7 M | 25.5 M | 22.5 M | 19.1 M | 17.7 M | 17 M | 14.4 M | 14 M | 13.9 M | 12.6 M | 11 M | 11.2 M |
All numbers in USD currency
Quarterly Income Statement LeMaitre Vascular
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
22.7 M | 22.6 M | 22.6 M | 22.5 M | 22.5 M | 22.4 M | 22.3 M | 22.2 M | 22.1 M | - | 22 M | 22 M | 21.9 M | - | 21.6 M | 20.6 M | 20.5 M | - | 20.3 M | 20.2 M | 20.2 M | - | 19.9 M | 19.7 M | 19.6 M | - | 19.5 M | 19.3 M | 19.3 M | - | 19.1 M | 18.8 M | 18.6 M | - | 18.5 M | 18.4 M | 18.3 M | - | 17.9 M | 17.6 M | 17.4 M | - | 17.3 M | 16.1 M | 15.6 M | - | 15.3 M | 15.2 M | 15.2 M | - | 15.1 M | 15.2 M | 15.3 M | - | 15.5 M | 15.5 M | 15.5 M |
Net Income |
17.4 M | 13.8 M | 11 M | 11.1 M | 11.8 M | 9.89 M | 7.5 M | 8.1 M | 6.04 M | - | 5.46 M | 3.52 M | 6.04 M | 6.18 M | 6.5 M | 8.3 M | 5.93 M | 7.03 M | 7.51 M | 3.5 M | 3.17 M | 4.61 M | 5.18 M | 4.62 M | 3.51 M | 6.02 M | 4.31 M | 8.75 M | 3.85 M | 4.28 M | 5.04 M | 4.63 M | 3.22 M | 2.6 M | 3.23 M | 2.6 M | 2.17 M | 2.53 M | 2.09 M | 1.77 M | 1.37 M | 1.92 M | 934 K | 1.27 M | -207 K | 746 K | 721 K | 889 K | 846 K | 698 K | 663 K | 824 K | 386 K | 346 K | 1.21 M | 519 K | 64 K |
Revenue |
61 M | 64.2 M | 59.9 M | 54.8 M | 55.8 M | 53.5 M | 47.4 M | 50.1 M | 47.1 M | - | 39 M | 42.1 M | 39.6 M | 39.5 M | 38.4 M | 40.7 M | 35.9 M | 37.5 M | 36.4 M | 24.9 M | 30.6 M | 30.2 M | 29.1 M | 29.5 M | 28.5 M | 28.4 M | 24.2 M | 27 M | 26 M | 26.2 M | 24.8 M | 25.8 M | 24.1 M | 23.3 M | 23.2 M | 22.4 M | 20.3 M | - | 19 M | 19.9 M | 18.9 M | - | 17.5 M | 18.2 M | 16.8 M | - | 15.3 M | 16 M | 15.4 M | - | 13.6 M | 14.4 M | 13.9 M | - | 14.6 M | 15.1 M | 14.6 M |
Cost of Revenue |
15.1 M | 19.3 M | 18.5 M | 17.6 M | 17.4 M | 16.8 M | 16.6 M | 18 M | 16.2 M | - | 14 M | 14.3 M | 13.6 M | - | 13.5 M | 13.9 M | 12.1 M | - | 13.7 M | 7.82 M | 10.1 M | - | 8.93 M | 9.17 M | 9.02 M | - | 6.91 M | 8.03 M | 7.52 M | - | 7.24 M | 8.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
46 M | 45 M | 41.4 M | 37.2 M | 38.5 M | 36.7 M | 30.8 M | 32.1 M | 30.9 M | - | 25.1 M | 27.8 M | 26 M | 26 M | 24.9 M | 26.8 M | 23.8 M | 24.4 M | 22.7 M | 17 M | 20.5 M | 19.9 M | 20.2 M | 20.3 M | 19.5 M | 19.2 M | 17.3 M | 19 M | 18.5 M | 18.3 M | 17.6 M | 17.5 M | 17.4 M | 16.2 M | 17 M | 15.4 M | 14.4 M | 14.4 M | 13.5 M | 13.1 M | 13.1 M | 12.8 M | 12 M | 12.4 M | 11.2 M | 12 M | 10.7 M | 11.2 M | 11.2 M | 10.4 M | 10 M | 10.5 M | 9.87 M | 9.52 M | 10.2 M | 10.4 M | 10.2 M |
Operating Income |
20.3 M | 16.1 M | 12.6 M | 13.1 M | 14.4 M | 11.9 M | 9.18 M | 9.45 M | 7.87 M | - | 6.15 M | 5.78 M | 7.93 M | 8.3 M | 9.07 M | 11.1 M | 7.94 M | 9.54 M | 10 M | 4.87 M | 4.35 M | 4.93 M | 5.9 M | 5.92 M | 4.44 M | 7.19 M | 4.61 M | 11.5 M | 4.86 M | 6.32 M | 5.05 M | 5.54 M | 4.19 M | 3.91 M | 5.34 M | 3.78 M | 3.3 M | - | 3.32 M | 2.79 M | 2.31 M | - | 1.85 M | 1.98 M | -231 K | - | 776 K | 1.45 M | 1.12 M | - | 1 M | 1.46 M | 854 K | - | 1.99 M | 897 K | -30 K |
Interest Expense |
1.3 M | 1.3 M | 1.29 M | - | - | - | - | - | - | - | - | - | - | - | 621 K | 495 K | 577 K | - | 665 K | 66 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6 K | - | - | - | 6 K | 8 K | 4 K | - | - | - | - | - | 2 K | 8 K | 8 K |
EBITDA |
21.8 M | 17.6 M | 15.2 M | 14.6 M | 15.9 M | 14.3 M | 10.7 M | 11 M | 10.2 M | - | 7.68 M | 7.38 M | 10.3 M | 8.3 M | 17.3 M | 12.7 M | 10.6 M | 9.54 M | 15.9 M | 8.05 M | 5.89 M | 4.93 M | 9.88 M | 8.54 M | 5.72 M | 7.19 M | 7.72 M | 13.6 M | 5.9 M | 6.32 M | 8.02 M | 7.5 M | 5.17 M | 3.91 M | 8 M | 5.6 M | 4.18 M | - | 5.82 M | 4.47 M | 3.14 M | - | 4.27 M | 3.6 M | 600 K | - | 2.75 M | 2.7 M | 1.73 M | - | 2.63 M | 2.56 M | 1.4 M | - | 3.46 M | 1.85 M | 431 K |
Operating Expenses |
25.6 M | 28.8 M | 28.8 M | 24 M | 24.1 M | 24.8 M | 21.6 M | 22.6 M | 23 M | - | 18.9 M | 22 M | 18 M | - | 15.8 M | 15.7 M | 15.9 M | - | 12.7 M | 12.2 M | 16.1 M | - | 14.3 M | 14.4 M | 15 M | - | 12.6 M | 7.45 M | 13.6 M | - | 12.5 M | 12 M | 13.2 M | - | 11.7 M | 11.6 M | 11.1 M | - | 10.2 M | 10.3 M | 10.8 M | - | 10.2 M | 10.4 M | 11.5 M | - | 9.94 M | 9.79 M | 10.1 M | - | 9.01 M | 9.09 M | 9.02 M | - | 8.19 M | 9.47 M | 10.2 M |
General and Administrative Expenses |
10.8 M | 10.4 M | 10.5 M | 8.93 M | 8.82 M | 9.01 M | 7.74 M | 7.72 M | 7.93 M | - | 7.23 M | 7.33 M | 7.25 M | - | 6 M | 6.2 M | 6.54 M | - | 5.9 M | 5.33 M | 5.19 M | - | 4.55 M | 4.53 M | 4.94 M | - | 3.98 M | 4.55 M | 4.7 M | - | 4.56 M | 3.75 M | 4.55 M | - | 3.6 M | 3.41 M | 3.34 M | - | 3.46 M | 3.3 M | 3.62 M | - | 3.76 M | 3.3 M | 3.32 M | - | 3.28 M | 3.07 M | 2.88 M | - | 2.89 M | 2.72 M | 2.67 M | - | 2.8 M | 2.87 M | 2.85 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company LeMaitre Vascular (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
$ 19.94 | -0.75 % | $ 10.2 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 9.26 | 6.38 % | $ 187 M | USA |
 |
Alcon
ALC
|
$ 79.57 | -1.74 % | $ 40.4 B |  Schweiz |
 |
ICU Medical
ICUI
|
$ 151.39 | 0.99 % | $ 3.69 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 8.25 | -0.12 % | $ 170 M | USA |
 |
AtriCure
ATRC
|
$ 37.13 | 0.54 % | $ 1.74 B | USA |
 |
electroCore
ECOR
|
$ 6.69 | 0.41 % | $ 36.9 K | USA |
 |
Haemonetics Corporation
HAE
|
$ 65.86 | -1.2 % | $ 3.31 B | USA |
 |
AngioDynamics
ANGO
|
$ 10.49 | 1.25 % | $ 429 M | USA |
 |
The Cooper Companies
COO
|
$ 79.85 | -1.88 % | $ 15.9 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.5 | 0.76 % | $ 21.2 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 81.09 | - | $ 4.72 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 119.19 | -0.21 % | $ 5.77 B | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Repro Med Systems
KRMD
|
$ 5.7 | 5.75 % | $ 260 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 157.39 | 1.86 % | $ 4.91 B | USA |
 |
OraSure Technologies
OSUR
|
$ 2.92 | 4.48 % | $ 217 M | USA |
 |
Masimo Corporation
MASI
|
$ 136.51 | -0.6 % | $ 7.28 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 499.69 | -0.9 % | $ 177 B | USA |
 |
STERIS plc
STE
|
$ 263.11 | 0.14 % | $ 25.9 B | USA |
 |
Microbot Medical
MBOT
|
$ 1.8 | -0.28 % | $ 18.4 M |  Israel |
 |
Nephros
NEPH
|
$ 4.39 | 1.86 % | $ 45.6 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.28 | -2.77 % | $ 22.3 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Utah Medical Products
UTMD
|
$ 62.1 | 1.7 % | $ 225 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 23.18 | -1.19 % | $ 3.99 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 12.27 | -1.64 % | $ 2.49 B | USA |
 |
Pro-Dex
PDEX
|
$ 39.83 | 1.53 % | $ 131 M | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 13.62 | -1.52 % | $ 654 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 202.67 | -0.44 % | $ 58.3 B | USA |
 |
Repligen Corporation
RGEN
|
$ 150.69 | 0.88 % | $ 8.4 M | USA |
 |
ResMed
RMD
|
$ 252.29 | -2.33 % | $ 36.9 B | USA |
 |
BioLife Solutions
BLFS
|
$ 22.06 | 1.19 % | $ 1.02 B | USA |
 |
Stereotaxis
STXS
|
$ 2.2 | 0.23 % | $ 178 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.7 | 0.3 % | $ 21 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 18.21 | -3.91 % | $ 895 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 103.45 | -0.9 % | $ 4.85 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 233.48 | 1.0 % | $ 17 B | USA |